Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Level 2 - randomized trial
Double-blind randomized controlled crossover trial
PubMed 16826400 · doi:10.1007/s00213-006-0457-5
What was done
A double-blind crossover trial evaluated the acute and 2-month psychological effects of oral psilocybin (30 mg/70 kg) compared with an active control, methylphenidate hydrochloride (40 mg/70 kg). Participants were 36 hallucinogen-naive adults reporting regular participation in religious or spiritual activities. Thirty volunteers received psilocybin and methylphenidate in counterbalanced order across individual 8-hour sessions separated by 2-month intervals in supportive conditions. Six additional volunteers received methylphenidate in their first two sessions and unblinded psilocybin in a third session to obscure the design. Measures included in-session monitor behavioral ratings, immediate and 2-month participant-rated drug effect and mystical experience questionnaires, and community observer assessments of participant attitudes and behavior.
What was found
The abstract reports no numerical values, test statistics, or p-values. Psilocybin acutely produced perceptual changes, subjective experiences, labile moods including anxiety, and increased mystical experience scores relative to methylphenidate. At 2 months, participants rated the psilocybin experience as possessing substantial personal meaning and spiritual significance, attributing to it sustained positive changes in attitudes and behavior that were corroborated by community observer ratings.
Why it matters
This study provided early rigorous experimental evidence that psilocybin can reliably occasion profound mystical-type experiences with enduring personal significance, catalyzing modern psychedelic science and clinical research.
Limits
The abstract provides no quantitative data or effect sizes. The sample was small (n = 36) and limited to hallucinogen-naive individuals already engaged in religious or spiritual practices, restricting generalizability. Functional unblinding remains a significant concern despite an active control due to the distinctive psychoactive effects of high-dose psilocybin, and follow-up was limited to 2 months.
Cited by
- supports Healthy volunteers who receive psilocybin under supportive conditions frequently rate the experience months later as among the top five most personally meaningful and spiritually significant of their lives.
- supports Approximately 30% of research volunteers in controlled psilocybin sessions report experiencing significant fear or anxiety for some duration of the session.
- supports In the initial Johns Hopkins psilocybin study with hallucinogen-naive participants, high-dose methylphenidate was utilized as an active control, and participants were informed they could receive any of 11 different psychoactive compounds.